Left ventricular hypertrophy and geometry in type 2 diabetes patients with chronic kidney disease. An echocardiographic study

MP BAYAULI, FB LEPIRA, PK KAYEMBE, JR M’BUYAMBA-KABANGU

Abstract

Objective: We assessed left ventricular structural alterations associated with chronic kidney disease (CKD) in Congolese patients with type 2 diabetes.

Methods: This was a cross-sectional study of a case series. We obtained anthropometric, clinical, biological and echocardiographic measurements in 60 consecutive type 2 diabetes patients (37 females, 62%) aged 20 years or older from the diabetes outpatient clinic, University of Kinshasa Hospital, DRC. We computed creatinine clearance rate according to the MDRD equation and categorised patients into mild (CrCl > 60 ml/min per 1.73 m²), moderate (CrCl 30–60 ml/min per 1.73 m²) and severe CKD (< 30 ml/min per 1.73 m²).

Results: Compared to patients with normal kidney function, CKD patients had higher uric acid levels (450 ± 166 vs 306 ± 107 µmol/l; p ≤ 0.001), a greater proportion of LVH (37 vs 14%; p ≤ 0.05) and longstanding diabetes (13 ± 8 vs 8 ± 6 years; p ≤ 0.001). Their left ventricular internal diameter, diastolic (LVDD) was (47.00 ± 6.00 vs 43.00 ± 7.00 mm; p ≤ 0.001), LVMI was (47 ± 19 vs 30 ± 15 g/m²; p ≤ 0.05) and proportions of concentric (22 vs 11%; p ≤ 0.05) or eccentric (15 vs 3%; p ≤ 0.05) LV were also greater. Severe CKD was associated with increased interventricular septum, diastolic (IVSD) (12.30 ± 3.08 vs 9.45 ± 1.94 mm; p ≤ 0.05), posterior wall thickness, diastolic (PWTDD) (11.61 ± 2.78 vs 9.52 ± 1.77 mm; p ≤ 0.01), relative wall thickness (RWT) (0.52 ± 0.17 vs 0.40 ± 0.07; p ≤ 0.01) rate of LVH (50 vs 30%; p ≤ 0.05), and elevated proportions of eccentric remodelling (25 vs 15%; p ≤ 0.05) and concentric LVH (42 vs 10%; p ≤ 0.05) in comparison with patients with moderate CKD. In multivariable adjusted analysis, hyperuricaemia emerged as the only predictor of the presence of LVH in patients with CKD (adjusted OR 9.10; 95% CI: 2.40–33.73).

Conclusion: In keeping with a higher rate of cardiovascular events usually reported in patients with impaired renal function, CKD patients exhibited LVH and abnormal LV geometry.

Keywords: type 2 diabetes, chronic kidney disease, left ventricular hypertrophy, prevalence, predictors

Prevention of cardiovascular disease (CVD) requires early detection and correction of predisposing conditions and risk factors in susceptible subjects. Diabetes is a major risk factor for CVD, the prognosis of which lies not only in the level of plasma glucose but also in associated factors such as left ventricular hypertrophy (LVH). Such an association holds more risk for black people, whose high propensity to diabetic nephropathy has often been documented. There is a need to document the impact of renal function on CV morbidity and mortality in diabetic patients with CKD, particularly blacks. The aim of the present study was to evaluate the association between CKD and LV structural alterations in a clinic-based sample of consecutive Congolese patients with type 2 diabetes mellitus.

Methods

We enrolled in the present study consecutive type 2 diabetes subjects aged 20 years and older attending the outpatient clinic...
at the University of Kinshasa Hospital. Ethical approval was obtained from the institutional ethics review board and informed consent was obtained from the study participants. Exclusion criteria included ischaemic heart disease (IHD), acute coronary syndrome (ACS), congestive heart failure (CHF, NYHA class II or greater), valvular heart disease, cerebral infarction or transient ischaemic attack (TIA).

Self-reported physical activity, alcohol use and smoking habits, known duration of diabetes mellitus, current treatments and measures of adiposity [body mass index (BMI) and waist circumference] were obtained in all patients. Overweight and obesity were classified as BMI ≥ 25 kg/m² and ≥ 30 kg/m², respectively. Central obesity was categorised as waist circumference > 102 cm in men and > 88 cm in women.

Blood pressure (BP) was measured in the supine position using a mercury sphygmomanometer with an appropriate cuff on the left arm; the average of two readings was used for statistical analysis. Pulse pressure (PP) calculated as systolic blood pressure (SBP) minus diastolic blood pressure (DBP) was considered increased when > 60 mmHg.14 Hypertension was defined as BP > 140/90 mmHg or currently on antihypertensive treatment. Heart rate was counted over a full minute.

A 12-hour overnight fasting venous blood sample was collected for measurement of total cholesterol and its sub-fractions [low-density lipoprotein cholesterol (LDL-C) high-density lipoprotein cholesterol (HDL-C)], triglycerides (TG), plasma glucose, serum uric acid and creatinine levels. LDL-C was calculated according to the Friedewald formula.14 Dyslipidaemia was an LDL-C level ≥ 2.6 mmol/l or HDL-C < 1.03 mmol/l or TG ≥ 1.69 mmol/l.

According to the NCEP-ATP III guidelines,16 the metabolic syndrome (MS) was, in addition to diabetes, the presence of two of the following risk factors: BP > 130/85 mmHg or current antihypertensive treatment, central obesity as defined above, HDL-C < 1.03 mmol/l and/or TG > 1.69 mmol/l.

We computed glomerular filtration rate [creatinine clearance (CrCl)] using the MDRD equation.11 Chronic kidney disease (CKD) was a CrCl rate < 60 ml/min per 1.73 m²; it was stratified into mild (CrCl ≥ 60 ml/min per 1.73 m²), moderate (CrCl: 30–60 ml/min per 1.73 m²) and severe (CrCl < 30 ml/min per 1.73 m²).12 A uric acid level > 416 µmol/l defined hyperuricaemia. Proteinuria was a 24-hour urine protein excretion rate > 0.3 g.

Echocardiographic examination was performed with the patient in the partial left lateral decubitus position using an Acuson 128XP/10° machine with a 3.5-MHz transducer. Two-dimensional guided M-mode measurements were obtained as recommended by the American Society of Echocardiography (ASE).13

We used the Devereux modified cubed formula to calculate left ventricular mass (LVM).14 To account for gender and body size variations, LVM was indexed to height15, with a boundary of 51 g/m²² to define LVH in both genders.15 Relative wall thickness (RWT) was calculated as 2 × PWTD (posterior wall thickness, diastolic)/L VIDD (left ventricular internal diameter, diastolic). It was considered increased when > 0.45.16 RWT and left ventricular mass index (LVMl) were used to characterise LV geometry as normal (normal LVMl and normal RWT), concentric remodelling (normal LVMl and increased RWT), concentric hypertrophy (increased LVMl and normal RWT), LV ejection fraction (LVEF) was calculated using Tiechloz’s formula.17

**Statistical analysis**

Data are expressed as mean ± standard deviation (SD) or relative frequency in per cent. The distribution of duration of hypertension and triglyceride levels being positively skewed, the non-parametric Mann-Whitney test was used for these variables. Chi-square and Student t-tests were used for comparing categorical and normally distributed continuous variables, respectively.

Multiple regression models and the likelihood ratio method were performed with LVH as the dependent variable for the assessment of the strength and independence of association with risk factors. Adjusted odds ratio (aOR) were calculated for each variable from a model which included all these variables; the resulting aOR allowed the direct comparison of the independent effects of these variables to decide which variable has the greater effect on LVH. All statistical analyses were performed with SPSS for Windows, version 18.0. A p-value ≤ 0.5 was considered statistically significant.

**Results**

Tables 1 and 2 show clinical and biological characteristics of patients according to renal function. Mean age and duration of diabetes were 58 ± 8 and 11 ± 8 years, respectively for the whole group. BMI, waist circumference, SBP and DBP, and plasma glucose levels averaged 26 ± 5 kg/m², 95 ± 12 cm, 148 ± 26 mmHg, 84 ± 13 mmHg, and 8.10 ± 3.31 mmol/l, respectively. Diabetes was frequently associated with other CV risk factors, among which hypertension (80%) was the commonest. Clustering of risk factors into the metabolic syndrome was observed in 58% of patients.

Besides antidiabetic therapy, 97% of patients were receiving BP-lowering drugs. CKD was observed in 32 patients (53%), 20 of whom (62%) had a CrCl rate of 30 ml/min per 1.73 m² or higher. Compared to those with normal renal function, the duration of diabetes was longer (13 ± 8 vs 8 ± 6 years; p ≤ 0.001), the proportion of patients on current antihypertensive drugs greater (42 vs 25%; p < 0.05) and the level of uric acid higher (450 ± 166 vs 306 ± 107 µmol/l; p ≤ 0.001) in CKD patients. The two subgroups were similar for the other variables.

Table 3 summarises echocardiographic measurements by renal function status and Table 4 by the severity of renal dysfunction. Patients with CKD had increased LVDD (47.00 ± 6.00 vs 43.00 ± 7.00 mm; p ≤ 0.001), LVMl (47.00 ± 19 vs 36.00 ± 15.00 mm; p ≤ 0.05) and higher proportions of LVH (37 vs 14%; p ≤ 0.05); they also showed higher proportions of concentric (22 vs 11%; p ≤ 0.05) and eccentric (15 vs 3%; p ≤ 0.05) LVH.

Compared to patients with moderate CKD, those with severe CKD had increased interventricular septum thickness, diastolic (IVSD) (12.30 ± 3.08 vs 9.45 ± 1.94 mm; p ≤ 0.001), RWT (0.52 ± 0.17 vs 0.40 ± 0.07 mm; p ≤ 0.01) and higher proportions of LVH (50 vs 30%; p ≤ 0.05). Concentric remodelling (25 vs 15%; p ≤ 0.05) and concentric hypertrophy (42 vs 10%; p ≤ 0.05) were the geometric patterns most frequently encountered in patients with severe CKD. Between groups, systolic function indices did not differ.

In multivariable adjusted analysis, the probability of LVH...
among CKD patients was increased by hyperuricaemia (aOR 9.10; 95% CI: 2.40–33.74) for the presence versus the absence of hyperuricaemia.

Discussion

The key finding of the study was that the elevated prevalence of chronic kidney disease in our diabetic patients was associated with abnormal cardiac structure. The alteration in renal function was moderate in the majority of cases. Left ventricular mass index, the frequency of left ventricular hypertrophy and uric acid levels were higher in CKD patients in whom multivariable adjusted analysis indicated uric acid as the only predictor of LVH.

The elevated prevalence of moderate to severe CKD has been reported in 15 to 23% of diabetic patients in which it predicts the occurrence of CVD. The mechanisms by which chronic hyperglycaemia may induce cardiovascular and renal dysfunction include enhanced polyol pathway flux, altered redox state, increased formation of diacylglycerol (DAG) and subsequent activation of protein kinase C (PKC) isofoms, and accelerated

| TABLE 1. CLINICAL CHARACTERISTICS OF THE WHOLE GROUP AND DIABETICS WITH AND WITHOUT CKD |
|---------------------------------------------------------------|
| **Characteristic** | **Whole group** | **Normal renal function** | **CKD** |
|-------------------|----------------|--------------------------|--------|
| Gender: M/F       | 23/37          | 11/17                    | 12/20  |
| Age (years)       | 58 ± 8         | 59 ± 8                   | 58 ± 8 |
| Duration DM (years) | 11 ± 8         | 8 ± 6                    | 13 ± 8*** |
| Central obesity (%) | 62             | 32                      | 30     |
| AHT (%)           | 80             | 37                      | 43     |
| MS (%)            | 58             | 28                      | 30     |
| Antidiabetic drugs (%) | 97         | 45                      | 52     |
| Antihypertensive drugs (%) | 67    | 25                      | 42**   |
| Smoking (%)       | 10             | 7                       | 3      |
| BMI (kg/m²)       | 26 ± 5         | 27 ± 6                   | 26 ± 5 |
| Waist (cm)        | 95 ± 12        | 96 ± 13                  | 95 ± 12 |
| SBP (mmHg)        | 148 ± 26       | 148 ± 29                 | 149 ± 23 |
| DBP (mmHg)        | 84 ± 13        | 86 ± 15                  | 82 ± 11 |
| PP (mmHg)         | 64 ± 21        | 61 ± 23                  | 67 ± 19 |
| Heart rate (beats/min) | 83 ± 15       | 83 ± 20                  | 86 ± 12 |

Data are expressed as mean ± SD or relative frequency in per cent. CKD, chronic kidney disease; M, male; F, female; DM, diabetes mellitus; AHT, arterial hypertension; MS, metabolic syndrome; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 in comparison with normal renal function.

| TABLE 2. BIOLOGICAL CHARACTERISTICS OF THE PATIENTS AND DATA ACCORDING TO RENAL FUNCTION |
|---------------------------------------------------------------|
| **Characteristic** | **Whole group** | **Normal renal function** | **CKD** |
|-------------------|----------------|--------------------------|--------|
| TC (mmol/l)       | 5.61 ± 1.62    | 5.74 ± 1.40              | 5.62 ± 1.71 |
| LDL-C (mmol/l)    | 3.80 ± 1.54    | 3.90 ± 1.42              | 3.73 ± 0.78 |
| HDL-C (mmol/l)    | 1.45 ± 0.67    | 1.44 ± 0.51              | 1.53 ± 0.84 |
| TG (mmol/l)       | 1.60 ± 1.30    | 1.84 ± 1.80              | 1.33 ± 0.78 |
| Glucose (mmol/l)  | 8.10 ± 3.31    | 8.27 ± 2.77              | 7.80 ± 3.80 |
| Uric acid (µmol/l) | 410 ± 178      | 309 ± 107                | 500 ± 166*** |
| CrCl (ml/min/1.73 m²) | 64 ± 41        | 97 ± 35                  | 35 ± 18 |
| 24-h proteinuria (g) | 0.79 ± 1.72    | 0.07 ± 0.164             | 1.42 ± 2.17 |

Data are expressed as mean ± SD CKD, chronic kidney disease; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; CrCl, creatinine clearance. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 in comparison with normal renal function.

| TABLE 3. M-MODE ECHOCARDIOGRAPHIC DATA IN THE WHOLE GROUP AND DIABETICS WITH AND WITHOUT CKD |
|---------------------------------------------------------------|
| **Characteristic** | **Whole group** | **Normal renal function** | **CKD** |
|-------------------|----------------|--------------------------|--------|
| LV dimension | LVDD (mm) | 44.83 ± 6.62 | 43.00 ± 7.00 | 47.0 ± 6.00*** |
|                  | LVIDS (mm) | 29.67 ± 8.43 | 28.04 ± 7.72 | 31.09 ± 8.98 |
|                  | IVSD (mm)  | 10.42 ± 2.60 | 10.30 ± 2.41 | 11.00 ± 3.48 |
|                  | PWTD (mm)  | 9.98 ± 2.26 | 10.00 ± 2.00 | 10.00 ± 2.23 |
|                  | RWT        | 0.46 ± 0.13  | 0.47 ± 0.12  | 0.45 ± 0.13  |
|                  | LVM (g/m²) | 41.83 ± 17.72 | 36.00 ± 15.00 | 47.00 ± 19.00* |
|                  | EF (%)     | 68.25 ± 19.06 | 69.24 ± 17.02 | 67.39 ± 20.91 |
|                  | FS (%)     | 0.34 ± 0.13 | 0.34 ± 0.13 | 0.34 ± 0.14 |
| LV geometry      | Normal (%) | 43            | 44            |            |
|                  | Concentric remodelling (%) | 30 | 43 | 19* |
|                  | Concentric hypertrophy (%) | 17 | 11 | 22* |
|                  | Eccentric hypertrophy (%) | 10 | 3  | 15* |

Data are expressed as mean ± SD or relative frequency in per cent. CKD, chronic kidney disease; LVDD, left ventricular internal diameter, diastolic; LVIDS, left ventricular internal diameter, systolic; IVSD, interventricular septum, diastolic; PWTD, posterior wall thickness, diastolic; RWT, relative wall thickness; LVM, left ventricular mass index; EF, ejection fraction; FS, fraction shortening. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 in comparison with normal renal function.

| TABLE 4. SEVERITY OF RENAL DYSFUNCTION AND M-MODE ECHOCARDIOGRAPHIC DATA AMONG DIABETICS WITH CKD |
|---------------------------------------------------------------|
| **Characteristic** | **CrCl ≥ 30 ml/min** | **CrCl < 30 ml/min** |
|-------------------|----------------------|---------------------|
|                  | (n = 20)             | (n = 12)            |
| LV dimension | LVDD (mm) | 46.75 ± 5.72 | 46.75 ± 6.79 |
|                  | LVIDS (mm) | 30.90 ± 7.96 | 32.08 ± 7.80 |
|                  | IVSD (mm)  | 9.45 ± 1.94  | 12.30 ± 3.08* |
|                  | PWTD (mm)  | 9.12 ± 1.77  | 11.61 ± 2.78** |
|                  | RWT        | 0.40 ± 0.07  | 0.52 ± 0.17** |
|                  | LVM (g/m²) | 45.32 ± 15.74 | 52.41 ± 22.40 |
|                  | FS (%)     | 0.35 ± 0.15  | 0.32 ± 0.11  |
| LV geometry      | Normal, % | 55            | 25*            |
|                  | Concentric remodelling (%) | 15 | 25* |
|                  | Concentric hypertrophy (%) | 10 | 42* |
|                  | Eccentric hypertrophy (%) | 20 | 8* |

Data are expressed as mean ± SD or relative frequency in per cent. CKD, chronic kidney disease; CrCl, creatinine clearance; LVDD, left ventricular internal diameter, diastolic; LVIDS, left ventricular internal diameter, systolic; IVSD, interventricular septum, diastolic; PWTD, posterior wall thickness, diastolic; RWT, relative wall thickness; LVM, left ventricular mass index; EF, ejection fraction; FS, fraction shortening. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 in comparison with moderate CKD.
non-enzymatic formation of advanced glycation end products (AGEs). The DAG–PKC pathway affects cardiovascular and renal structure and function in many ways, e.g. the regulation of endothelial permeability, vascular tone, cell growth, angiogenesis, and cytokine and leucocyte activation. Moreover, insulin resistance/hyperinsulinaemia-induced activation of the sympathetic nervous and renin–angiotensin–aldosterone systems could contribute to cardiovascular and renal damage through oxidative stress and inflammation.

Alteration in kidney function predominated in patients with a longer duration of diabetes, enhancing the effect of both chronic hyperglycaemia and the ageing process. The latter is associated with changes in vascular structure and function due to clustering of multiple risk factors, including insulin resistance/hyperinsulinaemia, oxidative stress and inflammation. Arterial stiffness, an independent predictor of morbidity and mortality, has been reported to increase with age and is associated with high systolic and pulse pressure. Moreover, the decrease in the number of nephrons, which occurs with ageing, may result in hyperfiltration, hypertrophy and elevation in glomerular capillary pressure.

The high prevalence of LVH in CKD patients found in our study agrees with that of other studies. LVH in CKD is thought to result partly from uraemia-associated risk factors such as anaemia, calcium–phosphate products and hyperhomocysteinemia. Moreover, renal dysfunction activates the renin–angiotensin–aldosterone system, with subsequent formation of angiotensin II, known to be essential for the development and progression of LVH. The risk of CVD and death increases with the decline in glomerular filtration rate (GFR) and the major increase in risk occurs at a GFR < 60 ml/min per 1.73 m².

LVH has been reported to predispose to ischaemic heart disease, arrhythmias and congestive heart failure. Our results indicate that patients with severe CKD had higher proportions of abnormal LV geometry, with concentric remodelling and concentric hypertrophy as the most frequent pattern. Both eccentric and concentric hypertrophy may occur in individuals with CKD. Eccentric hypertrophy is thought to result from volume overload, leading to cardiomyocyte drop out. Concentric hypertrophy is typically the result of hypertension and increased afterload and is exacerbated by anaemia, hyperparathyroidism and high angiotensin II concentrations. Eccentric and concentric hypertrophy have different impacts on the prognosis. Concentric hypertrophy confers the worst prognosis, followed by eccentric hypertrophy and concentric remodelling.

Moderate CKD and a high proportion of hypertension could explain the pre-eminence of concentric hypertrophy observed in the present study. In Nigerian hypertensive patients, Aje et al. reported greater systolic, diastolic, pulse and mean blood pressure among patients with concentric hypertrophy in comparison with those with normal geometric patterns.

In our study, hyperuricaemia emerged as the only predictor of LVH in CKD patients. The mechanisms that could account for increased uric acid levels in CKD include overproduction to counteract oxidative stress and endothelial dysfunction, the severity of diabetes and/or hypertension, impaired renal uric acid clearance, and insulin resistance/hyperinsulinaemia-induced proximal renal tubular reabsorption of sodium and urate. The association between hyperuricaemia and LVH could rely upon an association of uric acid with other risk factors, either isolated or combined in the metabolic syndrome. The coexistence of hyperuricaemia and LVH has been recognised as an independent and powerful predictor of CVD.

The interpretation of the results of our study is confounded by some limitations. The cross-sectional design of the work precludes any causal relationship between CKD and associated risk factors. Moreover, the sample size did not allow sufficient power to detect additional associations. One wonders to what extent the conclusions of this clinic-based study could be extrapolated to the general population, given the bias in the referral of patients. The findings of our study bear, however, some clinical implications for CKD identification, treatment protocol and estimated prognosis in hypertensive patients.

Conclusion

This study has shown that LVH is common among type 2 diabetes patients with CKD. Concentric LVH was the geometric LV pattern most frequently encountered and its frequency increased with the decline in renal function. Hyperuricaemia emerged as the unique independent predictor of the risk of LVH.

The authors thank Prof JJ Muyembe, head of the National Institute of Biomedical Research/Ministry of Health, for the facilities obtained for the measurements of cholesterol and its sub-fractions. Particular thanks go to Prof E Kintoki, Division of Cardiology and Dr M Lelo, Division of Radiology and Imaging, Department of Internal Medicine, University of Kinshasa Hospital for their contribution to the evaluation of left ventricular mass and geometry.

References

1. Srivastava PM, Calafiori P, Maciaca R, Patel SK, Thomas MC, Jerums G, Burell LM. Prevalence and predictors of cardiac hypertrophy and dysfunction in patients with type 2 diabetes. Clin Sci 2008; 114(4): 313–320.
2. Foppa M, Duncan BB, Arnett DK, Benjamin EI, Liebson PR, Manolio TA, Skelton TN. Diabetes, gender, and left ventricular structure in African-Americans: the atherosclerosis risk in communities study. Cardiovasc Ultrasound 2006; 4: doi: 10.1186/1476-7210-4-43.
3. London GM. Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant 2002; 17(Suppl. 1): 29–36.
4. Berl T, Henrick W. Kidney-heart interactions: epidemiology, pathogenesis and treatment. Clin J Am Soc Nephrol 2006; 1: 8–18.
5. Schoffrin E, Lipman ML, Mann JFE. Chronic kidney disease. Effects on the cardiovascular system. Circulation 2007; 116: 85–97.
6. Ulasii II, Arodive EB, Ijoma CK. Left ventricular hypertrophy in African black patients with chronic renal failure at first evaluation. Ethn Dis 2006; 16(4): 859–864.
7. Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin Dial 2003; 16(2): 101–105.
8. Paolotti E, Bellino D, Cassottana P, Rolla D, Cannella G. Left ventricular hypertrophy in non diabetic proladyasis chronic kidney disease. Am J Kidney Dis 2005; 46(2): 320–327.
9. Friedewald WT, Levy RJ, Fredrickson DS. Estimation of the concentration of LDL-cholesterol without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–508.
10. National Heart Lung and Blood Institute. Executive Summary of the Third Report of National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486–2497.
11. Levey AS, Greene T, Kusek JW. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000; 11: A0828.
12. K/DOQI, Clinical practical guidelines for chronic kidney disease (CKD): Evaluation, Classification and Stratification. Kidney Disease Outcome Quality Initiative. *Am J Kidney Dis* 2002; 39(2 Suppl): S22–S26.

13. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. *Circulation* 1978; 58: 1072–1083.

14. Devereux RB, Alonso DR, Lucas EM, Gottlieb E, Sachs J, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. *Am J Cardiol* 1986; 57: 450–458.

15. De Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, Alderman MH. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. *J Am Coll Cardiol* 1992; 20: 1251–1260.

16. Savage DD, Garrison RJ, Kannel WB, Levy D, Anderson SJ, Stokes J, Feinlib M, Castelli WP. The spectrum of left ventricular hypertrophy in a general population sample: the Framingham Study. *Circulation* 1987; 75: 126–133.

17. Teicholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence in the presence of absence of synergy. *Am J Cardiol* 1976; 37: 7–11.

18. Lu B, Song X, Dong X, Yang Y, Zhang Z, Wen J, et al. High prevalence of chronic kidney disease in population-based patients diagnosed with type 2 diabetes in downtown Shanghai. *J Diabetes Complic 2008; 22(2): 96–103.*

19. Lemley KV. Diabetes and chronic kidney disease: lessons from the Pima Indians. *Pediatr Nephrol* 2008; 23(1): 1934–1940.

20. Das Eveme N, King GL. The role of protein kinase C activation and the vascular complications of diabetes. *Pharmacol Res* 2007; 55(6): 498–510.

21. Reaven GM, Littell H, Landsberg L. Hypertension and associated metabolic abnormalities–the role of insulin resistance and the sympathoadrenal system. *N Engl J Med* 1996; 334: 374–381.

22. Ritz E. Metabolic syndrome and kidney disease. *Blood Purif* 2008; 26(1): 59–62.

23. Paravivini TM, Touyz RM. NAD (P)H oxidase, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. *Diabetes Care* 2008; 31 (Suppl. 2): S170–S180.

24. Kis E, Cesprekai O, Horvath Z, Katona G, Fekete BC, Hrajka L, et al. Pulse pressure velocity in end-stage renal disease: influence of age and body dimensions. *Pediatr Res* 2008; 63(1): 95–98.

25. Minutolo R, Borrelli S, Chiodini P, Sciglione R, Bellizzi V, Cinciaruso B, et al. Effects of age on hypertensive status in patients with chronic kidney disease. *J Hypertens* 2007; 25(11): 2325–2333.

26. Laurent S, Bouterpyre P. Arterial Stiffness: a new surrogate end point for cardiovascular disease. *J Nephrol* 2007; 20(Suppl. 12): S45–S50.

27. Sturm G, Kollerits B, Neyer U, Ritz E, Kronenberg F, for the MMKD Study Group. Uric acid as a risk factor for progression of non diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. *Exp Gerontol* 2008; 43(4): 347–352.

28. Nardi E, Cottone S, Mule G, Palermo A, Cusimano P, Cerasola G. Influence of chronic renal insufficiency on left ventricular diastolic function in hypertensives without left ventricular hypertrophy. *J Nephrol* 2007; 20(3): 320–328.

29. Agaba EL. Characteristics of type 2 diabetics presenting with end-stage renal disease at the Jos University Hospital, Nigeria. *West Afr J Med* 2004; 23(2): 142–145.

30. Alebiosu CO, Odusan O, Famiiont OB, Juwesimi AE. Cardiovascular risk factors in type 2 diabetic Nigerians with clinical diabetic nephropathy. *Cardiovasc J S Afr* 2004; 15(3): 124–128.

31. Kanda T, Wakino S, Hayashi K, Plutzky J. Cardiovascular disease and type 2 diabetes mellitus: Proceeding with caution at a dangerous intersection. *J Am Soc Nephrol* 2008; 19: 4–7.

32. Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawanoy U. Uric acid, left ventricular mass index and risk of cardiovascular disease in essential hypertension. *Hypertension* 2006; 47(2): 195–202.

33. Ha SK, Park HS, Kim SJ, Park CH, Kim DS, Kim HS. Prevalence and patterns of left ventricular hypertrophy in patients with predialysis chronic renal failure. *J Korean Med Sci* 1998; 13: 488–494.

34. Aje A, Alededey AA, Oladope OS, Oda A, Ogah US, Oji DB, Falase AD. Left ventricular patterns in newly presenting Nigerian hypertensives: An echocardiographic study. *BMC Cardiovasc Disorders* 2006; 6: 4.

35. Viazzi F, Parodi D, Leoncini G, Parodi A, Falqui V, Ratto E, et al. Serum uric acid and target organ damage in primary hypertension. *Hypertension* 2005; 45: 991–996.

36. Talaat KM, el-Shelikh AR. The effect of mild hyperuricemia on urinary Transforming Growth Factor beta and the progression of chronic kidney disease. *Am J Nephrol* 2007; 27(5): 435–440.

37. Choncol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, et al. Relationship of uric acid with progression of kidney disease. *Am J Kidney Dis* 2007; 50(2): 239–247.

38. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzoli, et al. A role for uric acid in the progression of renal disease. *Am J Soc Nephrol* 2002; 13: 2888–2897.